Rapid and sustained relief of airway obstruction is a therapeutic aim which is still only rarely achieved in chronic bronchitis or asthma. Although the topical administration of adrenergic smooth muscle relaxants usually affords a rapid symptomatic improvement in these patients, the duration of relief is limited, and the efficacy of this treatment diminishes as breathlessness increases. There is clearly a need for more effective and longer lasting drugs. This communication is primarily concerned with the variations that were observed in the response to aerosols of isoprenaline sulphate and atropine methonitrate after their administration to patients at different phases of airway obstruction. The protective action of some drugs against artificially induced airway obstruction was also investigated.
METHODS AND MATERIALS
ESTIMATION OF AIRWAY RESISTANCE Serial F.E.V. and vital capacity values were determined by the author using the same direct writing spirometer throughout. A minimum of three F.E.V.1 recordings were determined for each test before estimating the slow vital capacity, after which a further one to three F.E.V.1 estimations were repeated. The results were plotted to indicate the order of each attempt. When the values progressively diminished, as usually occurred during acute phases of airway obstruction, the F.E.V.1 was calculated as the average of the last three attempts. In the majority of cases, consecutive F.E.V.1 values were similar or increased during the first few attempts; in these circumstances the average of the three highest values was calculated as the F.E.V.1. DRUG ADMINISTRATION Drug administration was carried out under strict supervision; aerosols were administered in rooms set aside for this purpose, and only one type of drug was administered in each room. Patients received no isoprenaline for three hours, and no atropine for 12 hours, before tests. All aerosol drugs were administered from a Wright nebulizer operating on compressed air, and a different set of apparatus was used for each type of drug. Aqueous solutions usually contained 5% propylene glycol (0-2% sodium metabisulphite was also included in the stock solutions containing isoprenaline).
AEROSOL DOSE The weight loss from the nebulizer and tubing, operating at 6 and 8 1./min. air flow, was approximately 150 and 220 mg./min.respectively. The maximum calculated dose (referred to below) is an approximate estimate of the dose of drug delivered to the face mask during the inspiratory period. The calculation was based on the total weight loss, and losses due to evaporation were not taken into account.
MINIMUM EFFECTIVE DOSE OF ISOPRENALINE SULPHATE
AEROSOL Test doses of isoprenaline were administered during five slow maximal inhalations from a Wright nebulizer operating at 6 1./min. air flow (total inspiratory time approximately 15 seconds). In a given subject, the dose inhaled was altered by varying the concentration of the isoprenaline solution between the ranges of 0-05 and 1.0%. The F.E.V.1 was determined three to five minutes after the test aerosol, after which an inhalation of 1.0% isoprenaline was administered for 60 seconds, and the maximum F.E.V.1 increase from the initial control value was assessed three to five minutes later. The F.E.V.1 improvement after the test aerosol was calculated as a percentage of the maximal F.E.V.1 increase. In the majority of tests the administration of a maximum calculated dose equivalent to less than 0-1 mg. of isoprenaline was sufficient to induce 90 Variation of drug action on airway obstruction in man stration of three types of spasmogen: histamine, carbachol or antigen in sensitized patients. The maximum percentage fall in the F.E.V.1 which followed the selected dose of spasmogen aerosol was calculated (control fall). Subsequently, the prophylactic dose of the drug under investigation was followed at varying time intervals by the standard spasmogen challenge, and the maximum percentage fall in the F.E.V.1 was determined (test fall). Drug effect was calculated from the formula control fall -test fall % protection= x 100 control fall Control experiments established that histamine challenge sufficient to induce a 20 to 40% fall in the F.E.V.1 could be repeated at least twice at hourly intervals without any significant alteration in the magnitude of the response. Carbachol has a slightly longer action, but repeatable results followed challenges at 90-minute intervals. A single antigen challenge led to a variable temporary desensitization, but antigen administered at a minimum of three-day intervals was satisfactory. In order to observe the maximum effect, serial F.E.V.1 values were estimated at two, five, and 15 minutes after the start of histamine or carbachol challenge, and at five-minute intervals, for a minimum of 30 minutes, after antigen.
CLASSIFICATION OF PATIENTS Ninety-six patients (61 male, 35 female, aged 14 to 73 years, average age 47 years) with spirometric evidence of airway obstruction were investigated as out-patients. The majority were assessed at regular two-to four-week intervals throughout the year; on the average, each patient in this series attended 59 times over a period of 39 months.
The differential diagnosis between chronic bronchitis and intrinsic or extrinsic asthma was difficult to make on the basis of the history and clinical findings alone; moreover, in some patients each Protective action against spasmogen challenge The protection afforded by aerosol atropine methonitrate against carbachol, histamine, and antigen challenge in the same subject is shown in Figs. 1, 2 , and 3 respectively.
Atropine is clearly more specific in its action as compared with isoprenaline, and although some protection against both histamine and antigen challenge was demonstrated it is of a low order. Clinical response to atropine methonitrate aerosol The approximate minimum dose of atropine methonitrate that could induce a maximum F.E.V.1 increase was investigated by the administration of aerosols containing varying concentrations of the drug. Cartridges with a known quantity of atropine as a finely divided powder were also prepared, so that a predetermined quantity of drug could be dispersed into the inspired air stream.
In the majority of tests, it was found that a maximum calculated dose of between 0005 and 0-05 mg. of atropine was sufficient to induce a maximum effect.
In some cases the maximum response was not apparent for 30 to 60 minutes after atropine administration. Larger doses, or the administration of tertiary atropine salts, e.g., atropine sulphate, did not significantly affect the time required for the maximum response to develop. The maximum increase in the F.E.V.1 was assessed in 94 patients after five inspirations of a 0-2% aqueous aerosol of atropine methonitrate (maximum calculated dose, 0 07 mg. Variation of drug action on airway obstruction in man patients tested during periods of increased airway resistance showed a significant and progressive decline of the atropine response compared with the isoprenaline response (assessed from similar basal conditions). Two patients in this group, as well as two similar cases not included in this series, showed a negative response to atropine. The inhalation of an aerosol of distilled water also effected some increase in the airway resistance in these patients.
Group B patients (Fig. 8) showed a more uniform response. In the majority of these subjects, atropine induced an effect equal to or greater than the corresponding isoprenaline response. There did not appear to be any correlation between the prevailing degree of airway obstruction and the relative efficacy of atropine in group B patients. Fig. 9 ) showed considerable variation in their responses. The duration of effect was apparently correlated with the relative degree of airway obstruction prevailing in each patient at the time of test. The majority showed a sustained effect, which persisted for several hours when they were well, but the duration of effect was progressively reduced as the relative degree of basal airway obstruction increased. In contrast, in the majority of group B patients (not responsive to corticosteroids, Fig. 10 Fig. 11 .
The administration of the combined drugs clearly afforded a considerably longer period of relief in all the patients tested. There was no evidence that this effect could be significantly prolonged by increasing the dose of the combined drugs. It Patients with seasonal asthma were the exception, as they showed a marked increase in sensitivity coincident with the onset of the asthma season. In two of these cases the increase in the sensitivity to histamine was shown to parallel a corresponding increase in sensitivity to specific antigen; both forms of hypersensitivity persisted during the asthma season in spite of corticosteroid therapy which was adequate to restore the basal F.E.V.L to within the normal range. In contrast, in patients with proven grass-pollen sensitivity, who showed evidence of persistent airway obstruction even during the winter months, a high degree of histamine sensitivity was demonstrated through- Variation of drug action on airway obstruction in man out the year. Tests with aerosols of carbachol, citric acid, propylene glycol, and other irritants confirm the clinical impression that chronic air flow obstruction is associated with a persistent hypersensitivity to a wide variety of irritants.
DISCUSSION
The short action of isoprenaline reported above confirms the observations of Lowell, Curry, and Schiller (1949) , and of Bresnick, Beakey, Levinson, and Segal (1949) , who conducted spasmogen challenge experiments after the administration of oral, parenteral, and aerosol isoprenaline.
Rapid metabolic inactivation of isoprenaline can be observed in sputum (expectorated a few minutes after isoprenaline inhalations) in which the pink-brown adrenochrome derivates are sometimes mistaken for blood. This rapid degradation together with diffusion probably accounts for the absence of any significant prolongation of action after the administration of large doses of isoprenaline. By contrast, mepyramine, which is not actively metabolized in the lung, showed a significantly longer duration of action when the dose was increased (Fig. 2) . Attempts to block the enzymatic degradation of isoprenaline by the simultaneous administration of ortho-methyltransferase inhibitors have been unsuccessful (unpublished results), but it is possible that this approach can lead to the development of longeracting adrenaline derivatives.
The prolongation of therapeutic action beyond the period when its presence can be demonstrated by spasmogen challenge tests implies that the factors responsible for airway obstruction are acting slowly. The duration of this 'free wheel' period, during which a reduced airway resistance is apparently maintained in the absence of drug, is an indication of the activity of the noxious processes causing airway obstruction; when the duration of 50% effect is less than 45 minutes, considerable improvement may be anticipated; a similar decrease occurring at 90 minutes or later indicates that the patient is in a phase of relative remission.
Atropine, or its analogues, has been used to relieve respiratory distress for over 150 years (Finnegan, 1950) , but conflicting reports of its therapeutic value continue to appear (Palmer, 1962; Chamberlain, Muir, and Kennedy, 1962) . Some of the apparent discrepancies in the literature can be explained on the basis of the results presented above. Hume and Jones (1961) administered atropine as a 4-0% aqueous aerosol but F.E.V.l changes were estimated for only 15 minutes after drug administration, so that the maximum effect of atropine may not have been observed in some cases. The side effects which these workers reported were not observed in the present study in which much lower doses were used.
Herxheimer (1959) , who administered atropine sulphate as a smoke as well as as a wet aerosol, reported an effective duration of less than three hours. His results with atropine sulphate were confirmed in this study (Fig. 6) ; the quaternary salt, however, was shown to have a longer duration, lasting up to six hours.
It is apparent that a number of factors can influence the outcome of atropine therapy; failure to recognize these factors has led to conflicting opinions in the past. The selection of patients, the phase of disease, the choice of atropine derivative, the dose and method of administration, and the period of observation can all affect the results.
The mechanism of action of atropine therapy on airway obstruction is of interest. Armitage, Herxheimer, and Rosa (1952) reported that atropine has significant anti-anaphylactic properties when tested by the micro-shock technique on guinea-pigs, but the potent antihistamines were much more effective. The anti-anaphylactic properties of atropine in the guinea-pig can perhaps be attributed entirely to its weak antihistaminic action. In man (Fig. 3) , both atropine and potent antihistamines are virtually ineffective against experimentally induced allergic airway obstruction. This suggests that histamine is probably not the major spasmogen released from human lung after anaphylactic challenge (Brocklehurst, 1956) . On the other hand, Dautrebande, Lovejoy, and McCredie (1962) Williams (1961) on isolated guinea-pig atrial muscle. He reported that the contractility and electrical behaviour of the muscle was altered in opposite directions by acetylcholine and histamine. Most of these effects, he considers, could be attributed to an increase in membrane permeability to potassium and sodium induced by acetylcholine and histamine respectively. It is possible that the contractile properties of human bronchial muscle are also influenced in opposite directions by histamine and acetylcholine. Thus, although atropine is an effective 'competitive inhibitor' at the acetylcholine receptor site, and correspondingly less effective at the histamine receptors, it may also alter the basic-tone of the muscle fibre by opposing the permeability changes induced by acetylcholine. The slow onset of the atropine response, as measured by F.E.V. lincrease, in contrast to its immediate effect against carbachol challenge, may be accounted for by the time required to establish a new equilibrium in the muscle fibres after a change in permeability. Absence of effect and, in some cases, an increased airway resistance which follows the administration of atropine to 'allergic' subjects may also be explained on this basis. These subjects liberate excessive quantities of histamine (as shown by eosinophilic sputum), so that under these abnormal conditions the consequences of the permeability changes induced by histamine may be partially held in check by the opposing action of acetylcholine; the administration of atropine could then enhance the action of histamine and lead to increased airway obstruction.
From the clinical standpoint, estimations of the relative efficacy and duration of action of atropine methonitrate, in comparison with isoprenaline, can help to distinguish between 'allergic' and 'nonallergic' airway obstruction. When a patient is already receiving corticosteroids, a good atropine response implies adequate control; a poor response to atropine indicates inadequate corticosteroid control, possibly as a result of other factors such as infection.
Quantitative estimations of airway obstruction induced by specific antigen or non-specific spasmogen challenge can be of assistance in the assessment of therapy. It is evident that curative therapy will reduce the abnormally high level of airway irritability which is observed in all patients with 'chronic bronchitis' or asthma.
SUMMARY OF RESULTS
The magnitude and duration of effect of isoprenaline, atropine derivatives, and three types of spasmogen administered as aerosols were estimated in a group of patients at varying phases of increased airway resistance. The duration of the F.E.V.1 increase after isoprenaline inhalation served as a useful index of the relative degree of airway obstruction which was present in a given patient at the time of test.
No clinically significant prolongation of effect was achieved by increasing the dosage up to the limit of tolerance.
ATROPINE THERAPY Atropine was shown to be a poor antagonist of both antigen and histamine induced airway obstruction.
Compared with isoprenaline, atropine therapy afforded significantly greater relief as well as a more prolonged effect in patients not susceptible to corticosteroids. Patients who benefit from corticosteroids also responded well to atropine during phases of relative remission.
The action of quaternary atropine derivates, e.g., atropine methonitrate, administered topically, was sustained longer than that of the corresponding tertiary salts, e.g., atropine sulphate.
Of the commonly used antispasmodic drugs, isoprenaline and atropine were found to be the most effective.
SPASMOGEN CHALLENGE Histamine and other spasmogen challenge tests have provided precise, quantitative information on the mechanisrn of action and duration of effect of drugs acting on the bronchial musculature.
Hypersensitivity to irritants was observed in both 'allergic' and 'non-allergic' airway obstructive disease. Fluctuations of the basic level of susceptibility to irritants, induced by therapy or other factors, were assessed quantitatively by determining changes in sensitivity to standard spasmogen challenge.
Measurement of the magnitude of the response to atropine methonitrate compared with isoprenaline alone can be used to identify and assess the progress of patients who will respond to corticosteroid therapy.
